Mumps Drug Sales

Mumps Drug Sales Market Outlook

The global Mumps drug sales market is projected to reach approximately USD 2.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 6% during the forecast period from 2025 to 2035. The growth of this market can be attributed to several factors, including the increasing prevalence of mumps outbreaks in various regions, the rising awareness regarding vaccination, and the development of effective antiviral therapies. Additionally, government initiatives and public health campaigns aimed at controlling and preventing mumps have further fueled the demand for mumps drugs. Technological advancements in vaccine production and distribution methods are also expected to bolster market growth, as they enhance the accessibility and efficacy of mumps treatment options.

Growth Factor of the Market

One of the primary growth factors driving the Mumps drug sales market is the resurgence of mumps outbreaks in various countries, primarily due to declining vaccination rates. This alarming trend has prompted healthcare authorities to intensify vaccination campaigns and promote public awareness, thereby increasing the demand for mumps vaccines. Furthermore, the rising incidence of viral infections, including mumps, in densely populated urban areas has put additional pressure on healthcare systems, creating a favorable environment for the growth of the mumps drug market. The development of new formulations and delivery systems for existing antiviral drugs has also contributed to market expansion, as they offer improved patient compliance and treatment outcomes. Additionally, increasing investments by pharmaceutical companies in research and development of innovative treatment options for mumps are expected to significantly contribute to market growth over the forecast period.

Key Highlights of the Market

• The global Mumps drug sales market is expected to grow at a CAGR of 6% from 2025 to 2035.
• Increasing awareness regarding vaccination and rising prevalence of mumps outbreaks are key growth drivers.
• Technological advancements in vaccine production are enhancing accessibility and efficacy.
• Government initiatives are promoting public health campaigns to control mumps.
• Investments in R&D for innovative treatment options are rising among pharmaceutical companies.

By Product Type

Vaccines:

Vaccines represent the most significant segment in the Mumps drug sales market. The majority of mumps vaccines available today are live attenuated vaccines, which are generally administered in combination with other vaccines for measles and rubella (MMR). These vaccines are highly effective in preventing mumps infection and have been instrumental in significantly reducing the incidence of the disease. In light of recent mumps outbreaks, there has been a renewed focus on vaccination programs, which is expected to drive the demand for mumps vaccines even further in the upcoming years. Governments and health organizations are also emphasizing the need for booster doses to enhance immunity, thereby increasing the overall market for vaccines in combating mumps.

Antiviral Drugs:

Antiviral drugs for mumps are observed to be a growing niche within the market, as there is an increasing need for effective treatment options for individuals infected with the virus. Currently, there are no specific antiviral drugs dedicated solely to mumps; however, certain antiviral medications can be used off-label to manage symptoms and reduce the duration of illness. This segment is likely to see growth as research progresses in developing targeted antiviral therapies specifically for mumps. The increasing prevalence of viral infections necessitates the development of such antiviral treatments, propelling innovation in this segment.

Pain Relievers:

Pain relievers, which primarily include over-the-counter medications such as acetaminophen and ibuprofen, are widely used to alleviate symptoms associated with mumps, including fever and discomfort. The accessibility and widespread use of these pain relievers make this segment a vital component of the Mumps drug sales market. Physicians often recommend pain relievers as a supportive treatment for managing symptoms in patients affected by mumps, leading to consistent demand in this category. The simplicity and effectiveness of pain relievers ensure they will remain essential in managing mild cases of mumps, sustaining their position in the market.

Fever Reducers:

Fever reducers, which include medications like ibuprofen and acetaminophen, play a critical role in the management of mumps-related symptoms. These medications are used to alleviate fever and accompanying discomfort caused by the viral infection. The consistent demand for fever reducers is expected to maintain its momentum, particularly during seasonal outbreaks. Their over-the-counter availability and efficacy in symptom management make these products readily accessible to consumers, further solidifying their significance in the Mumps drug sales market. As more individuals become aware of the importance of managing symptoms effectively, the sales of fever reducers are anticipated to grow, contributing positively to market dynamics.

Anti-inflammatory Drugs:

Anti-inflammatory drugs, which are often used to manage the inflammatory responses associated with mumps, are essential in providing relief to patients suffering from the illness. These drugs can help reduce swelling, pain, and overall discomfort. They are especially beneficial for severe cases where inflammation becomes significant. The growing understanding and recognition of the effectiveness of anti-inflammatory medications in managing viral infections have led to increased usage in the context of mumps. As the number of mumps cases rises, along with the emphasis on comprehensive patient care, the demand for anti-inflammatory drugs is expected to increase, thus enhancing their contribution to the overall market.

By Application

Hospitals:

Hospitals represent one of the largest application segments in the Mumps drug sales market. They are often the first point of contact for patients presenting with symptoms of mumps. Healthcare professionals in hospitals play a critical role in diagnosing mumps, administering vaccines, and managing symptomatic treatment. The high patient turnover and the availability of comprehensive healthcare services in hospitals ensure a steady demand for mumps-related drugs. Moreover, hospitals are actively involved in vaccination campaigns, which further drives the consumption of mumps vaccines, significantly impacting the overall market.

Clinics:

Clinics, including outpatient care facilities and private practice offices, are also essential in the Mumps drug sales market. They provide convenient access to vaccines and treatment options for patients seeking immediate care for mumps symptoms. The increasing focus on preventive healthcare measures has led many clinics to prioritize vaccination programs, contributing to the demand for mumps vaccines. Additionally, clinics facilitate early diagnosis and management of mumps cases, leading to increased sales of supportive treatment products. As more individuals seek healthcare services outside hospitals, clinics will continue to play a vital role in the market.

Retail Pharmacies:

Retail pharmacies are a crucial distribution point for mumps-related drugs, particularly over-the-counter medications such as pain relievers and fever reducers. Their convenience and accessibility enable consumers to obtain necessary medications quickly, especially during mumps outbreaks. With the growing awareness of self-care and symptom management, retail pharmacies have observed an increase in the sales of pain management products. Furthermore, retail pharmacies often collaborate with healthcare providers to promote vaccination, enhancing their role in the Mumps drug sales market.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel in the Mumps drug sales market, particularly due to the growing trend of e-commerce in healthcare. The convenience of ordering medications online allows consumers to access mumps-related drugs without visiting physical stores, which has proven advantageous during outbreaks when social distancing measures are in place. This trend has been further accelerated by the COVID-19 pandemic, which has led to a surge in online shopping for pharmaceuticals. As more people become comfortable with purchasing healthcare products online, the role of online pharmacies in the Mumps drug sales market is expected to increase.

Others:

This segment encompasses various other applications that contribute to the Mumps drug sales market, including community health programs and mobile vaccination units. Such programs are vital for reaching populations that may be underserved or hesitant to seek traditional healthcare. By providing accessible vaccination and treatment options, these initiatives help enhance public health efforts to control mumps outbreaks. As the focus on public health initiatives grows, the "Others" segment is anticipated to gain relevance, further supporting the overall market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are significant distributors of mumps drugs, playing an essential role in ensuring that patients receive appropriate treatment during their hospital stay. These pharmacies are strategically placed within hospitals, providing immediate access to mumps vaccines and medications. Hospital pharmacies often stock a wide range of products, including antiviral drugs and supportive treatments, to cater to diverse patient needs. The direct relationship between hospital staff and pharmacy teams ensures that patients receive timely care, thereby enhancing the reliability of hospital pharmacies in the Mumps drug sales market.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for mumps drugs, particularly for over-the-counter medications such as pain relievers and fever reducers. These pharmacies are easily accessible to the general public and play a crucial role in symptom management during outbreaks. The rise of pharmacies offering immunization services has also contributed to the growth of mumps vaccine distribution through retail channels. As consumer awareness of preventive healthcare increases, retail pharmacies are expected to maintain their relevance and significance in the Mumps drug sales market.

Online Pharmacies:

Online pharmacies have gained substantial traction in the Mumps drug sales market, driven by the convenience and accessibility they offer to consumers. The ability to order medications and vaccines from the comfort of home has become increasingly appealing, particularly during health crises. Online pharmacies often provide competitive pricing and a broader selection of products, making them an attractive option for consumers seeking mumps-related drugs. As e-commerce continues to flourish, online pharmacies are positioned to expand their market share significantly, providing an important channel for the distribution of mumps drugs.

Drug Stores:

Drug stores play a vital role in the distribution of mumps drugs, acting as a bridge between manufacturers and consumers. These stores typically stock a wide range of medications, including prescription and over-the-counter products related to mumps. The accessibility of drug stores in various neighborhoods makes them a convenient option for individuals seeking treatment for mumps symptoms. Additionally, many drug stores have expanded their offerings to include vaccination services, which further enhances their contribution to the Mumps drug sales market. The continued emphasis on preventive care will ensure that drug stores remain an integral part of the market landscape.

Others:

This segment includes various other distribution channels, such as public health organizations and community clinics that serve as points of access for mumps drugs. These entities play a crucial role in ensuring that vulnerable populations receive necessary vaccinations and treatments. By facilitating broader outreach efforts, these channels contribute to public health initiatives aimed at controlling mumps outbreaks. As more community-based programs emerge, the importance of "Others" as a distribution channel is expected to grow, further enriching the Mumps drug sales market.

By Ingredient Type

Live Attenuated Vaccines:

Live attenuated vaccines are the cornerstone of mumps prevention and are widely used in vaccination programs worldwide. These vaccines contain weakened forms of the mumps virus, which stimulate an immune response without causing the disease itself. The effectiveness of live attenuated vaccines is well-documented, significantly reducing the incidence of mumps in vaccinated populations. The demand for these vaccines remains high due to their proven efficacy and the ongoing emphasis on vaccination campaigns to curb outbreaks. As public health initiatives focus on increasing vaccination coverage, the market for live attenuated vaccines is expected to grow substantially over the forecast period.

Inactivated Vaccines:

Inactivated vaccines for mumps are less common but serve as an alternative approach to immunization. These vaccines contain killed virus particles that stimulate an immune response without the risk of causing the disease. While inactivated vaccines are not the primary method for mumps prevention, their availability provides additional options for patients who may have contraindications to live attenuated vaccines. As research progresses in developing effective inactivated formulations, this segment has the potential to expand its presence in the Mumps drug sales market, especially among populations with specific health concerns.

Acetaminophen:

Acetaminophen is a widely used pain reliever and fever reducer that plays a crucial role in managing symptoms associated with mumps. Its accessibility as an over-the-counter medication makes it a popular choice for symptomatic relief among affected individuals. Acetaminophen is often recommended for patients experiencing discomfort due to fever and pain, contributing to its sustained demand in the mumps market. As healthcare providers continue to emphasize the importance of symptom management during viral infections, acetaminophen's significance in the Mumps drug sales market is expected to remain steady.

Ibuprofen:

Ibuprofen, another common pain reliever and anti-inflammatory drug, is frequently utilized for alleviating symptoms of mumps. It is effective in reducing fever and inflammation, making it an important option for symptomatic treatment. The over-the-counter availability of ibuprofen enhances its accessibility to consumers, and its dual action as both a pain reliever and anti-inflammatory agent makes it a preferred choice for managing mumps-related symptoms. As awareness of the importance of managing viral illness symptoms continues to grow, the demand for ibuprofen in the Mumps drug sales market is anticipated to increase.

Prednisone:

Prednisone, a corticosteroid, is sometimes used in more severe cases of mumps to manage inflammation and prevent complications associated with the infection. While not a standard treatment for mumps, its role in controlling severe inflammatory responses can be critical, especially in at-risk populations. The cautious use of prednisone in select cases may contribute to its presence in the Mumps drug sales market. However, the emphasis on preventive care and vaccination remains the primary focus, with prednisone serving as a supportive treatment option in specific scenarios.

By Region

North America holds a significant share of the global Mumps drug sales market, attributed to comprehensive vaccination programs and a high level of healthcare infrastructure. The region has seen recent mumps outbreaks, which have prompted health authorities to advocate for increased vaccination coverage and public awareness campaigns. With a projected CAGR of 7% from 2025 to 2035, North America is expected to continue leading the market due to ongoing public health efforts and increasing access to mumps vaccines and treatment options. The robust pharmaceutical industry in the region also enhances the availability of mumps-related drugs, ensuring that patients receive timely care.

Europe is another critical region in the Mumps drug sales market, characterized by a diverse healthcare landscape and varying vaccination adherence rates across countries. While some nations maintain high vaccination coverage, others have experienced declines, leading to an uptick in mumps cases. The European market is projected to grow steadily due to increasing awareness of mumps vaccination and initiatives targeting outbreak prevention. As healthcare systems continue to prioritize preventive measures and treatment availability, the demand for mumps drugs in Europe is expected to rise, contributing positively to the overall market.

Opportunities

One of the most promising opportunities in the Mumps drug sales market lies in the enhancement of vaccination programs. With increased public health awareness and campaigns aimed at educating communities about the importance of vaccinations, governments and healthcare organizations are more motivated than ever to invest in mumps vaccination initiatives. This drive toward public health improvement not only opens the door for higher vaccine sales but also creates a supportive environment for the development of new and innovative vaccine formulations. As more individuals gain access to effective vaccines, the incidence of mumps is likely to decline, creating a positive feedback loop that bolsters the market for mumps-related drugs.

Additionally, the ongoing research and development efforts aimed at creating more effective antiviral treatments for mumps present significant opportunities for market growth. As the healthcare industry continues to evolve, there is an increasing demand for targeted therapies that can effectively combat viral infections. Pharmaceutical companies are actively investing in R&D to explore novel antiviral compounds specifically designed for mumps, which could lead to advancements in patient care and treatment outcomes. The integration of new technologies and drug delivery systems in developing antiviral treatments can drive the Mumps drug sales market forward, positioning it for sustained growth over the next decade.

Threats

Despite the promising growth prospects for the Mumps drug sales market, several threats could hinder its progress. One of the most pressing challenges is the declining vaccination rates observed in certain regions, primarily due to vaccine hesitancy fueled by misinformation and concerns regarding vaccine safety. This decline poses a significant risk, as lower vaccination coverage can lead to increased outbreaks of mumps, thus straining healthcare resources and negatively impacting public health. If the trend of vaccine hesitancy continues, it could result in a more significant burden on the healthcare system, potentially limiting the market's growth as fewer individuals seek mumps-related treatments.

Another potential restrainer for the Mumps drug sales market is the emergence of alternative treatments and natural remedies that individuals may seek in place of conventional antiviral drugs and vaccines. As more consumers turn to holistic approaches to healthcare, this shift could challenge the traditional pharmaceutical market for mumps treatments. Additionally, the competitive landscape may also experience disruption as new entrants explore alternative treatment options that appeal to consumers looking for natural solutions. This trend could lead to decreased demand for established mumps drugs and vaccines, affecting overall market revenue.

Competitor Outlook

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Sanofi Pasteur
• Pfizer Inc.
• Novartis AG
• AstraZeneca plc
• Janssen Pharmaceuticals, Inc.
• Roche Holding AG
• Baxter International Inc.
• Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Limited
• BioNTech SE
• Regeneron Pharmaceuticals, Inc.
• Vaxart, Inc.
• Emergent BioSolutions Inc.

The competitive landscape of the Mumps drug sales market is characterized by the presence of several well-established pharmaceutical companies that dominate the market. These companies are recognized for their extensive expertise in vaccine development and antiviral drug production, providing them with a competitive advantage. Major players such as Merck & Co., Inc. and GlaxoSmithKline plc are at the forefront of the market, producing widely used mumps vaccines and actively engaging in public health initiatives to promote vaccination. The significant investments these companies make in research and development allow them to innovate continuously and maintain their market leadership, ensuring they remain competitive in the evolving landscape.

In addition to established players, new entrants are also emerging in the Mumps drug sales market, seeking to capitalize on the growing demand for vaccines and treatments. These companies often focus on developing novel formulations and delivery systems to improve patient compliance and treatment outcomes. As competition intensifies, established companies may also seek strategic partnerships and collaborations to expand their product offerings and reach new markets. This trend emphasizes the importance of staying ahead in the competitive landscape through innovation and adaptability to changing consumer preferences.

Furthermore, ongoing regulatory changes and evolving market dynamics present both challenges and opportunities for industry players. Companies operating in the Mumps drug sales market must navigate complex regulatory requirements while ensuring their products meet safety and efficacy standards. As the market evolves, successful players will be those who can effectively respond to these changes and adapt their strategies accordingly. The focus on public health initiatives and increased awareness of mumps vaccination will also shape the competitive landscape, as companies align their efforts to address growing concerns regarding vaccine-preventable diseases.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 BioNTech SE
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Vaxart, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi Pasteur
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hoffmann-La Roche Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Baxter International Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Emergent BioSolutions Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Janssen Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Mumps Drug Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 Online Pharmacies
    • 6.1.5 Others
  • 6.2 Mumps Drug Sales Market, By Product Type
    • 6.2.1 Vaccines
    • 6.2.2 Antiviral Drugs
    • 6.2.3 Pain Relievers
    • 6.2.4 Fever Reducers
    • 6.2.5 Anti-inflammatory Drugs
  • 6.3 Mumps Drug Sales Market, By Ingredient Type
    • 6.3.1 Live Attenuated Vaccines
    • 6.3.2 Inactivated Vaccines
    • 6.3.3 Acetaminophen
    • 6.3.4 Ibuprofen
    • 6.3.5 Prednisone
  • 6.4 Mumps Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Mumps Drug Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Mumps Drug Sales market is categorized based on

By Product Type

• Vaccines
• Antiviral Drugs
• Pain Relievers
• Fever Reducers
• Anti-inflammatory Drugs

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Acetaminophen
• Ibuprofen
• Prednisone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Sanofi Pasteur
• Pfizer Inc.
• Novartis AG
• AstraZeneca plc
• Janssen Pharmaceuticals, Inc.
• Roche Holding AG
• Baxter International Inc.
• Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Limited
• BioNTech SE
• Regeneron Pharmaceuticals, Inc.
• Vaxart, Inc.
• Emergent BioSolutions Inc.